基于HBsAg定量的HBsAg-HCC评分预测核苷经治CHB患者肝癌风险
该研究采用两队列设计,在1190例核苷(酸)类似物(NA)经治的慢性乙型肝炎(CHB)患者中通过Cox回归建立HBsAg-HCC评分,并在506例独立前瞻队列中验证。评分纳入HBsAg水平、年龄、性别、低蛋白血症和APRI,训练队列3/5/7年AUC为0.867/0.872/0.871,验证队列为0.784/0.780/0.777,均优于PAGE-B、mPAGE-B和aMAP。
要点
- HBsAg-HCC评分纳入HBsAg定量等5项指标,在NA经治CHB患者中显示良好预测效能。
- 训练队列3/5/7年AUC为0.867/0.872/0.871,显著优于PAGE-B、mPAGE-B和aMAP。
- 验证队列3/5/7年AUC为0.784/0.780/0.777,内外交叉验证支持其稳定性。
核心结论
- 纳入HBsAg定量的HBsAg-HCC评分可更全面、准确地用于NA经治CHB患者的HCC风险分层,弥补现有模型忽视病毒特异性标志物的不足。
研究设计与样本
- 采用两队列设计:回顾性训练队列纳入1190例NA经治CHB患者,以Cox回归筛选独立HCC风险因素并建立评分。
- 在独立前瞻性验证队列506例患者中验证评分,并与PAGE-B、mPAGE-B、aMAP三种现有工具比较。
主要发现
- 识别出5个独立HCC风险因素:较高HBsAg水平、较大年龄、男性、低蛋白血症和APRI升高。
- 训练队列3/5/7年AUC分别为0.867/0.872/0.871,显著优于PAGE-B、mPAGE-B和aMAP。
- 验证队列3/5/7年AUC分别为0.784/0.780/0.777,内部和外部交叉验证证实其稳定性与可靠性。
关键数值与推荐
- HBsAg-HCC评分由较高HBsAg水平、较大年龄、男性、低蛋白血症和APRI升高5个独立风险因素构建。
- 训练队列3/5/7年AUC为0.867/0.872/0.871,验证队列为0.784/0.780/0.777。
临床怎么用
- 对NA经治CHB患者可考虑使用HBsAg-HCC评分进行HCC风险分层,尤其适用于现有模型预测准确性不足时。
- 将HBsAg定量纳入常规HCC风险评估,有助于识别传统模型可能低估的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis B (CHB) virus infection is the leading cause of hepatocellular carcinoma (HCC). Nucleos(t)ide analogs (NAs) effectively suppress HBV replication, but residual HCC risk remains in treated patients, highlighting the need for reliable risk stratification tools. Existing prediction models rely heavily on age and liver function parameters and often overlook hepatitis B surface antigen (HBsAg) quantification, a key marker closely tied to HBV-related HCC, resulting in inadequate clinical predictive accuracy. METHODS: To address this gap, we developed the novel HBsAg-HCC Score using a two-cohort design: retrospective training (1190 NA-treated CHB patients) with Cox regression to identify independent HCC risk factors, followed by validation in an independent prospective cohort (506 patients). Its performance was compared with three established tools (PAGE-B, mPAGE-B, aMAP). RESULTS: Five independent HCC risk factors were identified: higher HBsAg levels, older age, male sex, hypoproteinaemia, and elevated APRI. The HBsAg-HCC Score derived from these factors showed strong predictive power: 3-/5-/7-year AUCs of 0.867/0.872/0.871 in the training cohort (significantly outperforming PAGE-B, mPAGE-B, aMAP) and 0.784/0.780/0.777 in the validation cohort. Internal and external cross-validation confirmed its stability and reliability. CONCLUSIONS: By incorporating HBsAg quantification, a virus-specific marker often missing from conventional models, the HBsAg-HCC Score offers a more comprehensive and accurate approach to HCC risk stratification in NAs-experienced CHB patients, addressing a critical limitation of existing models directly.
引用
- Guo YF, Niu XX, Li L, et al. HBsAg Quantification-Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs-Experienced Patients With Chronic Hepatitis B: The HBsAg-HCC Score. Aliment Pharmacol Ther. 2026. PMID: 41933428. doi:10.1111/apt.70652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。